Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Labianca

Showing results (161-170 of 174) with videos related to

Pageof 18
Sort By:
Tumori|December 24, 2016
Position paper of the Italian Association of Medical Oncology on early palliative care in oncology practice (Simultaneous Care)Vittorina Zagonel, Vittorio Franciosi, Antonella Brunello, et al.
Therapeutic Advances in Medical Oncology|February 4, 2020
Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trialSandro Barni, Gerardo Rosati, Sara Lonardi, et al.
Journal of the National Cancer Institute|April 19, 2007
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trialStefano Cascinu, Roberto Labianca, Carlo Barone, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2020
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiativeRomain Cohen, Dewi Vernerey, Carine Bellera, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2018
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD GroupKaitlyn K H Goey, Halfdan Sørbye, Bengt Glimelius, et al.
The Lancet. Oncology|March 7, 2018
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable diseaseEmil Ter Veer, L Bengt van Rijssen, Marc G Besselink, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2014
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)Franck Bonnetain, Bert Bonsing, Thierry Conroy, et al.
Eclinicalmedicine|July 12, 2023
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational studyMelissa Bersanelli, Elena Verzoni, Alessio Cortellini, et al.
Lung Cancer (Amsterdam, Netherlands)|December 15, 2010
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)Giuseppe Luigi Banna, Massimo Di Maio, Alessandro Follador, et al.
Therapeutic Advances in Medical Oncology|November 23, 2020
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOGMelissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, et al.
Pageof 18

Showing results (161-170 of 174) with videos related to

Sort By:
Pageof 18
Tumori|December 24, 2016
Position paper of the Italian Association of Medical Oncology on early palliative care in oncology practice (Simultaneous Care)Vittorina Zagonel, Vittorio Franciosi, Antonella Brunello, et al.
Therapeutic Advances in Medical Oncology|February 4, 2020
Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trialSandro Barni, Gerardo Rosati, Sara Lonardi, et al.
Journal of the National Cancer Institute|April 19, 2007
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trialStefano Cascinu, Roberto Labianca, Carlo Barone, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2020
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiativeRomain Cohen, Dewi Vernerey, Carine Bellera, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2018
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD GroupKaitlyn K H Goey, Halfdan Sørbye, Bengt Glimelius, et al.
The Lancet. Oncology|March 7, 2018
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable diseaseEmil Ter Veer, L Bengt van Rijssen, Marc G Besselink, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2014
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)Franck Bonnetain, Bert Bonsing, Thierry Conroy, et al.
Eclinicalmedicine|July 12, 2023
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational studyMelissa Bersanelli, Elena Verzoni, Alessio Cortellini, et al.
Lung Cancer (Amsterdam, Netherlands)|December 15, 2010
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)Giuseppe Luigi Banna, Massimo Di Maio, Alessandro Follador, et al.
Therapeutic Advances in Medical Oncology|November 23, 2020
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOGMelissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, et al.
Pageof 18